Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,305 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,823 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06953739 | A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL. | not yet recruiting | Phase 3 | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | May 1, 2025 | clinicaltrials |
| NCT06895512 | A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma | not yet recruiting | Phase 3 | 386 | Shanghai Henlius BiotechINDUSTRY |
| 1 |
| Mar 26, 2025 |
| clinicaltrials |
| NCT06742138 | To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma | not yet recruiting | Phase 3 | 284 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Dec 19, 2024 | clinicaltrials |
| NCT06613035 | Twice-per-weekSelinexor, 2 Days Melphalan | not yet recruiting | Phase 3 | 126 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT06573645 | A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL | not yet recruiting | Phase 3 | 428 | Xia YiOTHER | 0 | Aug 27, 2024 | clinicaltrials |
| NCT06548347 | A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma | not yet recruiting | Phase 2 / Phase 3 | 606 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Aug 12, 2024 | clinicaltrials |
| NCT06510530 | Astragalus for Symptomatic Alleviation in High-grade Lymphoma | not yet recruiting | Phase 3 | 60 | Bnai Zion Medical CenterOTHER_GOV | 1 | Jul 19, 2024 | clinicaltrials |
| NCT06465446 | A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma | not yet recruiting | Phase 3 | 202 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 0 | Jun 24, 2024 | clinicaltrials |
| NCT06297772 | Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR | not yet recruiting | Phase 3 | 220 | Ruijin HospitalOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06355401 | Maintenance Hormonal Therapy and DLBCL | not yet recruiting | Phase 2 / Phase 3 | 100 | Sohag UniversityOTHER | 0 | Apr 9, 2024 | clinicaltrials |
| NCT06314698 | Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease | not yet recruiting | Phase 3 | 478 | RenJi HospitalOTHER | 0 | Mar 18, 2024 | clinicaltrials |
| NCT06278896 | Early Neutropenic Fever De-escalation of Antibiotics Study(END) | not yet recruiting | Phase 3 | 260 | Brigham and Women's HospitalOTHER | 0 | Feb 26, 2024 | clinicaltrials |
| NCT05876832 | A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE) | not yet recruiting | Phase 3 | 312 | Shijiazhuang Yiling Pharmaceutical Co. LtdINDUSTRY | 0 | May 26, 2023 | clinicaltrials |
| NCT05205902 | TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides(TOTEM-01) | not yet recruiting | Phase 3 | 78 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Jan 25, 2022 | clinicaltrials |
Data updated 22 days agoSource updated May 1, 2025source: clinicaltrials